Leaderboards/Inflammatory Bowel Disease

Inflammatory Bowel Disease

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Alba Garrido-Trigo
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2
Peilin Guo
Institute of Process Engineering
3
Jiaying Zheng
Chinese University of Hong Kong
4
Chengxin Shi
First Affiliated Hospital of Xi'an Jiaotong University
5
Jiawei Guo
Southern University of Science and Technology
6
Paolo Cadinu
Boston Children's Hospital
7
Ruipeng Yang
Taiyuan Normal University
8
V Joustra
Amsterdam University Medical Centers
9
Zuoting Yu
Zhejiang University
10
Dahham Alsoud
KU Leuven

Papers

1
Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis
Cell Host & Microbe|2024
159 cit.
2
Publication in Nature Medicine (2024) [120 citations, W4403136141]
Nature Medicine|2024
120 cit.
3
Charting the cellular biogeography in colitis reveals fibroblast trajectories and coordinated spatial remodeling
Cell|2024
105 cit.
4
Publication in Inflammatory Bowel Diseases (2024) [33 citations, W4390829407]
Inflammatory Bowel Diseases|2024
33 cit.
5
Publication in Therapeutic Drug Monitoring (2024) [26 citations, W4395013233]
Therapeutic Drug Monitoring|2024
26 cit.
6
Publication (2024) [22 citations, W4404783584]
Unknown Journal|2024
22 cit.
7
Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study
˜The œLancet. Gastroenterology & hepatology|2025
14 cit.
8
Publication in Current Protocols (2025) [8 citations, W4408161747]
Current Protocols|2025
8 cit.
9
Publication in Clinical Gastroenterology and Hepatology (2024) [4 citations, W4403711811]
Clinical Gastroenterology and Hepatology|2024
4 cit.
10
Publication in United European Gastroenterology Journal (2025) [3 citations, W4412191252]
United European Gastroenterology Journal|2025
3 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Johan Burisch
University of Copenhagen
2
Ryan C. Ungaro
Feinstein Institute for Medical Research
3
Parambir S. Dulai
Northwestern Medicine
4
Dorothee Zimmermann
University of Zurich
5
Caterina Strisciuglio
University of Campania "Luigi Vanvitelli"
6
Esther Orlanski‐Meyer
Shaare Zedek Medical Center
7
David J. Gonzalez
University of California San Diego
8
Pritesh Morar
St Mark's Hospital
9
Robert V. Bryant
Queen Elizabeth Hospital
10
Ren Mao
Sun Yat-sen University

Papers

1
Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity
Nature Microbiology|2022
385 cit.
2
Location-specific signatures of Crohn’s disease at a multi-omics scale
Microbiome|2022
95 cit.
3
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
The American Journal of Gastroenterology|2022
68 cit.
4
High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course
Inflammatory Bowel Diseases|2022
65 cit.
5
Therapeutic Potential of the 4 Strategies to SUlfide-REduction (4-SURE) Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open-Label Feasibility Study
Journal of Nutrition|2022
46 cit.
6
Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Celiac Disease
Biomedicines|2022
44 cit.
7
Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD
Journal of Crohn s and Colitis|2022
44 cit.
8
The Impact of Periodontitis on Inflammatory Bowel Disease Activity
Inflammatory Bowel Diseases|2022
39 cit.
9
The Incidence and Prevalence of Paediatric- and Adult-Onset Inflammatory Bowel Disease in Denmark During a 37-Year Period: A Nationwide Cohort Study (1980–2017)
Journal of Crohn s and Colitis|2022
39 cit.
10
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis
Clinical Gastroenterology and Hepatology|2022
37 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
William J. Sandborn
University of San Diego
2
Stefan Schreiber
Christian-Albrechts-Universität zu Kiel
3
Jean‐Frédéric Colombel
Mount Sinai Hospital
4
Markus F. Neurath
Friedrich-Alexander-Universität Erlangen-Nürnberg
5
Warren Strober
Office of Extramural Research
6
Çharles N. Bernstein
University of Manitoba
7
Ramnik J. Xavier
Massachusetts General Hospital
8
Julián Panés
Hospital Clínic de Barcelona
9
Geert D’Haens
Amsterdam University Medical Centers
10
Séverine Vermeire
KU Leuven

Papers

1
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
New England Journal of Medicine|2005
3.9k cit.
2
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Cell Host & Microbe|2014
3.3k cit.
3
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
New England Journal of Medicine|2010
3.1k cit.
4
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
New England Journal of Medicine|2013
2.7k cit.
5
Trypan Blue Exclusion Test of Cell Viability
Current Protocols in Immunology|2015
2.6k cit.
6
Gut microbiome structure and metabolic activity in inflammatory bowel disease
Nature Microbiology|2018
2k cit.
7
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
Gut|2013
1.9k cit.
8
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1
Nature Genetics|2006
1.9k cit.
9
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
New England Journal of Medicine|2017
1.7k cit.
10
Cell Contact–Dependent Immunosuppression by Cd4+Cd25+Regulatory T Cells Is Mediated by Cell Surface–Bound Transforming Growth Factor β
The Journal of Experimental Medicine|2001
1.6k cit.

Reagents for Inflammatory Bowel Disease

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Cell Signaling TechnologyEvidence 65

Phospho-ATP-Citrate Lyase (Ser455) (F4T8R) Rabbit Monoclonal Antibody

Cited in 9 papers
#97366$200,479
View Evidence →

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

Phospho-BLNK (Thr152) (E4P2P) Rabbit Monoclonal Antibody

Cited in 8 papers
#62144$176,415
View Evidence →
Cell Signaling Technology

Human IFN-alpha-2b Recombinant Protein

Cited in 7 papers
#36000$110
View Evidence →
Cell Signaling TechnologyEvidence 64

PathScan® Phospho-Tau (Ser214) Sandwich ELISA Kit

Cited in 7 papers
#44177$66,129,740
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 65

ENPP1 (D37B7) Rabbit Monoclonal Antibody

Cited in 11 papers
#5342$179,416
View Evidence →
Cell Signaling TechnologyEvidence 63

Phospho-GSK-3 alpha/beta (Ser21/9) (37F11) Rabbit Monoclonal Antibody

Cited in 10 papers
#9327$179,968
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-ATP-Citrate Lyase (Ser455) (F4T8R) Rabbit Monoclonal Antibody

Cited in 9 papers
#97366$200,479
View Evidence →